Hadano, Japan

Yoshitami Ohashi

This inventor holds 2 USPTO granted patents. Top assignee: Wakamoto Pharmaceutical Co., Ltd.. Active years: 1993-1997.


% Patents Active = 100.0

Average Co-Inventor Count = 5.3

ph-index = 1

Forward Citations = 10(Granted Patents)


Location History:

  • Hatano, JP (1993)
  • Tokyo, JP (1997)

Company Filing History:


Years Active: 1993-1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Yoshitami Ohashi

Introduction

Yoshitami Ohashi is a notable inventor based in Hatano, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibiotics and diagnostic methods for renal diseases. With a total of 2 patents, his work has the potential to impact medical treatments significantly.

Latest Patents

Ohashi's latest patents include the antibiotic WAP-8294A and a method for diagnosing renal diseases. The antibiotic WAP-8294A is produced by a strain belonging to the genus Lysobacter and has shown excellent therapeutic effects against infectious diseases caused by Gram-positive bacteria, especially MRSA. The method for diagnosing renal diseases involves detecting fragments of albumin in human urine using immunological methods or liquid chromatography techniques.

Career Highlights

Ohashi is currently associated with Wakamoto Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work focuses on developing effective treatments for bacterial infections and improving diagnostic methods for kidney-related ailments.

Collaborations

Ohashi has collaborated with notable coworkers such as Haruhisa Hirata and Azusa Katou, contributing to the advancement of pharmaceutical research and development.

Conclusion

Yoshitami Ohashi's contributions to antibiotic development and renal disease diagnostics highlight his importance in the field of pharmaceuticals. His innovative work continues to pave the way for new treatments and diagnostic methods that can improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…